EOHILIA is a 12-week oral treatment for EoE in people 11 years and older. It has not been shown to be safe and effective for longer than 12 weeks.

Friends at a restaurant enjoying a pizza with a neon sign saying - turn the tables on EoE


The first and only FDA-approved oral treatment for eosinophilic esophagitis (EoE)

Ask your doctor if EOHILIA is right for you.

See if you’re eligible for the EOHILIA Patient Support and Copay Program.

What is EoE?

EoE is a chronic inflammatory disease that occurs in your esophagus—the tube that passes food and liquid from your throat down to your stomach. EoE causes inflammation in your esophagus, which can lead to it narrowing and symptoms like dysphagia (difficulty swallowing).


EOHILIA is a liquid-like form of budesonide (a known corticosteroid) designed to treat inflammation specific to the esophagus.


In a 12-week clinical study of 318 patients 11 years and older with EoE, 213 patients were treated with EOHILIA (2 mg twice daily), while 105 were given placebo.

After 12 weeks, EOHILIA was proven to:

Reduce difficulty swallowing

Patients taking EOHILIA achieved a
10.2-point reduction in their overall DSQ score from when they started the study, while patients on placebo had a 6.5-point difference.*

The Dysphagia Symptom Questionnaire (DSQ) biweekly score was based on patient self-reports of difficulty swallowing. Scores ranged from 0 to 84, with higher scores indicating greater frequency and severity of dysphagia.

Reduce inflammation in the esophagus

53% of patients taking EOHILIA had a decrease in the number of eosinophils in the esophagus compared to
1% of patients on placebo.†

Eosinophils are white blood cells that can contribute to inflammation.

In this 12-week clinical study, the most common side effects included:

Side effectsEOHILIA patients
Placebo patients
Respiratory tract infection
Fungal infections of the mouth, throat, and esophagus (thrush)8%2%
Infection of the stomach and intestine (gastroenteritis)3% 1%
Sore throat3%2%
Adrenal suppression2%0%
Acid-related damage to the lining of the esophagus (erosive esophagitis) 2%0%

Please talk to your doctor to learn more about EOHILIA and see the Prescribing Information(opens in a new tab) and Patient Information(opens in a new tab).

*Patients experiencing less difficulty swallowing: Improvement in trouble swallowing with EOHILIA was calculated using the Dysphagia Symptom Questionnaire (DSQ), a point-based self-assessment that patients took daily to track how frequently they experienced dysphagia symptoms and the severity of those symptoms while taking EOHILIA treatment. At the start of the study, the average biweekly DSQ score of patients taking EOHILIA was 30.3 and 30.4 for patients on placebo.


Patients with a reduction in eosinophils: 113 of 213 patients (53%) taking EOHILIA had a reduction in number of eosinophils vs 1 of 105 patients (1%) receiving placebo after 12 weeks. Reduction in eosinophils (a type of white blood cell) with EOHILIA was calculated by counting the number of eosinophils under a microscope before and after treatment. Successful treatment response was defined as a reduction in the number of eosinophils in the esophagus to 6 or fewer per high-power field. The high-power field is the area of a slide visible under the high magnification system of a microscope.